The Tumor Lysis Syndrome
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The tumor lysis syndrome is the most common disease-related emergency in children and adults with hematologic cancers. This review summarizes current strategies for risk assessment, prophylaxis, and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An important consideration with respect to safety in patients that may have a compromised immune system is that engineered bacterial products are likely to engage both innate and adaptive immunity in the event of release of the organism into the body following tumor lysis75, triggering inflammatory responses.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationTumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0177 · Cited by 792
Self-citationCairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036665 · Cited by 363
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationOral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Cited by
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
“Chromosome 17p deletion 19/49 (39) 12/53 (23) 31/102 (30)”
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
“Although tumor lysis syndrome usually can be readily discriminated from CRS on the basis of characteristic laboratory abnormalities such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia, it can sometimes be difficult to determine if CRS and tumor lysis syndrome occur concurrently [46].”
BackgroundVenetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Wei, A. H., Montesinos, P., Ivanov, V., DiNardo, C. D., Novak, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 763
Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
“Vomiting 23 (22) 5 (23) 6 (18) 12 (24) 0 0 0 0 Constipation 22 (21) 6 (27) 7 (21) 9 (18) 2 (2) 1 (5) 1 (3) 0 Headache 19 (18) 2 (9) 7 (21) 10 (20) 0 0 0 0 Anemia 18 (17) 7 (32) 6 (18) 5 (10) 16 (15) 7 (32) 5 (15) 4 (8) Cough 18 (17) 7 (32) 6 (18) 5 (10) 1 (1) 1 (5) 0 0 Neutropenia 18 (17) 4 (18) 8 (24) 6 (12) 12 (11)…”
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
“Clinical and laboratory TLS were considered as previously defined.(25)”
MethodDeveloping a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V. (2021) · Cancers · doi:10.3390/cancers13071572 · Cited by 363
“TLS is caused by cancer treatments; however, they can occur spontaneously themselves, discharging cancer contents into the bloodstream, clinically presenting as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia which can manifest and result in renal dysfunction [278].”
BackgroundFathallah-Shaykh, S. A., & Cramer, M. T. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2549-x · Cited by 346
“Urinary alkalinization has not been proven to be an effective treatment and is not indicated for the treatment of tumor lysis syndrome because it decreases calcium phosphate solubility [26].”
BackgroundInfluentialVenetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S., Jurczak, W., Mulligan, S. P., Schuh, A., Assouline, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6840 · Cited by 314
Lasko, T. A., Denny, J. C., & Levy, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066341 · Cited by 313
“In some neoplastic diseases such as acute leukemias, continuous white blood cell turnover raises uric acid concentration throughout the course of the disease, and tumor lysis syndrome [37] can occur with the bolus of purines released from cells after a chemotherapy treatment.”
BackgroundUric Acid and the Risks of Kidney Failure and Death in Individuals With CKD
Srivastava, A., Kaze, A. D., McMullan, C. J., Isakova, T., & Waikar, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.08.017 · Cited by 306
Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 282
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 264
“Due to the destruction of large amount of tumor cells, the rapid release of intracellular substances lead to a series of metabolic disorders such as hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and metabolic acidosis, which lead to life-threatening severe arrhythmia or acute renal failure [30].”
BackgroundTam, C. S., Allan, J. N., Siddiqi, T., Kipps, T. J., Jacobs, R., Opat, S., Barr, P. M., Tedeschi, A., Trentin, L., Bannerji, R., et al. (2022) · Blood · doi:10.1182/blood.2021014488 · Cited by 248
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Lv, X., Talukdar, M., Lu, Y., Wang, X., Hu, D. Z., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95873 · Cited by 239
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00807 · Cited by 233
Jones, G. L., Will, A., Jackson, G. H., Webb, N. J. A., & Rule, S. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13403 · Cited by 227
“There are a number of risk stratification models that have been proposed (Cairo et al, 2010; Howard et al, 2011).”
BackgroundTumor Lysis Syndrome: New Challenges and Recent Advances
Wilson, F. P., & Berns, J. S. (2013) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.07.001 · Cited by 221
Treating Childhood Cancer in Low- and Middle-Income Countries
Gupta, S., Howard, S. C., Hunger, S. P., Antillon, F. G., Metzger, M. L., Israëls, T., Harif, M., & Galindo, C. R. (2015) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0349-9_ch7 · Cited by 205
Self-citationAdverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Baldo, B. (2013) · OncoImmunology · doi:10.4161/onci.26333 · Cited by 191
Onconephrology: The intersections between the kidney and cancer
Rosner, M. H., Jhaveri, K. D., McMahon, B. A., & Perazella, M. A. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21636 · Cited by 192
Jonas, B. A., & Pollyea, D. A. (2019) · Leukemia · doi:10.1038/s41375-019-0612-8 · Cited by 183
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Sun, S., He, H., Yang, G., Zhang, Y., & Fu, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/2386187 · Cited by 183
CAR T-Cell Therapy in Hematological Malignancies
Haslauer, T., Greil, R., Zaborsky, N., & Geisberger, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168996 · Cited by 180
“Management of TLS should therefore include prevention of cardiac dysrhythmias as well as prevention of renal function [89].”
BackgroundCurrent Progress in CAR-T Cell Therapy for Hematological Malignancies
Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2021) · Journal of Cancer · doi:10.7150/jca.48976 · Cited by 179
“The symptoms of TLS had some similarities or overlap with CRS in some respects and can also lead to life-threatening severe arrhythmia[33].”
BackgroundCrombie, J. L., Graff, T., Falchi, L., Karimi, Y. H., Bannerji, R., Nastoupil, L. J., Thiéblemont, C., Ursu, R., Bartlett, N. L., Nachar, V. R., et al. (2024) · Blood · doi:10.1182/blood.2023022432 · Cited by 177
“17,18 Tumor lysis syndrome monitoring and prophylaxis should be performed in patients at increased risk based on factors such as disease histology, tumor burden, and baseline renal function.”
BackgroundPollyea, D. A., Pratz, K., Letai, A., Jonas, B. A., Wei, A. H., Pullarkat, V., Konopleva, M., Thirman, M. J., Arellano, M., Becker, P. S., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26039 · Cited by 166
“Laboratory and clinical TLS were identified as previously defined.(21) Per protocol, for patients with ongoing cytopenia(s) after morphologic clearance of leukemia, subsequent cycles of venetoclax and HMA could be delayed until ANC reached ≥500/μL or for up to 14 days to allow for blood count recovery.”
MethodMato, A. R., Thompson, M., Allan, J. N., Brander, D. M., Pagel, J. M., Ujjani, C. S., Hill, B. T., Lamanna, N., Lansigan, F., Jacobs, R., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193615 · Cited by 165
“TLS events were defined as per Howard criteria, which specify criteria for laboratory and clinical TLS.(14) Adverse events”
MethodDavids, M. S., Hallek, M., Wierda, W., Roberts, A. W., Stilgenbauer, S., Jones, J. A., Gerecitano, J. F., Kim, S. Y., Potluri, J., Busman, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3761 · Cited by 164
“None of these events met Howard criteria (19) for clinical TLS, and only two (1.”
BackgroundInfluentialThe role of adipose tissue senescence in obesity- and ageing-related metabolic disorders
Liu, Z., Wu, K. K. L., Jiang, X., Xu, A., & Cheng, K. K. Y. (2020) · Clinical Science · doi:10.1042/cs20190966 · Cited by 137
Sakemura, R., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., Miyao, K., Koyama, D., Goto, T., Hanajiri, R., Nishida, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0043 · Cited by 161
Nephrotoxicity of anticancer treatment
Małyszko, J., Kozłowska, K., Kozłowski, L., & Małyszko, J. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw338 · Cited by 159
Canet, E., Zafrani, L., Lambert, J., Thiéblemont, C., Galicier, L., Schnell, D., Raffoux, E., Lengliné, É., Chevret, S., Darmon, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055870 · Cited by 157
“Early identification of the etiologies of AKI is crucial to ensure appropriate treatment, such as adequate hydration, urate oxidase therapy to prevent uric acid-related nephropathy, and RRT to prevent acute nephrocalcinosis [25].”
BackgroundCytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
“When the accumulation of phosphate, potassium, xanthine, or uric acid is more rapid than excretion, the TLS develops [33].”
Oberoi, S., Lehrnbecher, T., Phillips, B., Hitzler, J. K., Ethier, M., Beyene, J., & Sung, L. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.01.004 · Cited by 156
Tumor lysis syndrome: A clinical review
Mirrakhimov, A. E., Voore, P., Khan, M., & Ali, A. M. (2015) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v4.i2.130 · Cited by 153
Howard, S. C., Trifilio, S. M., Gregory, T. K., Baxter, N., & McBride, A. (2016) · Annals of Hematology · doi:10.1007/s00277-015-2585-7 · Cited by 152
“This shift of intracellular constituents into the extracellular space may overcome normal homeostatic mechanisms, leading to TLS and life-threatening acute kidney injury, arrhythmias, and neurologic complications [1, 2].”
BackgroundSelf-citationTumor Lysis Syndrome in Patients with Hematological Malignancies
Belay, Y., Yirdaw, K., & Enawgaw, B. (2017) · Journal of Oncology · doi:10.1155/2017/9684909 · Cited by 146
“Malignancies with high cancer mass, bulky disease, large tumor burden, sensitivity of the malignancy to chemotherapy, cancer stage, and rapid proliferation rate of malignant cells are tumor specific factors related to TLS [11, 41, 43, 44].”
BackgroundInfluentialMcCurdy, M. T., & Shanholtz, C. B. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31824e1865 · Cited by 147
“The subject has been recently reviewed (114).”
Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder
Wiederkehr, M. R., & Moe, O. W. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9106-6 · Cited by 145
“Complications include acute urate nephropathy due to precipitation of uric acid and calcium phosphate crystals, and uric acid stones [66].”
In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 144
Coutre, S. E., Choi, M. Y., Furman, R. R., Eradat, H. A., Heffner, L. T., Jones, J. A., Chyla, B., Zhou, L., Agarwal, S., Waskiewicz, T., et al. (2018) · Blood · doi:10.1182/blood-2017-06-788133 · Cited by 148
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Zelenetz, A. D., Salles, G. A., Mason, K. D., Casulo, C., Gouill, S. L., Sehn, L. H., Tilly, H., Cartron, G., Chamuleau, M. E. D., Goy, A. H., et al. (2019) · Blood · doi:10.1182/blood-2018-11-880526 · Cited by 143
Onco-Nephrology: Tumor Lysis Syndrome
Wilson, F. P., & Berns, J. S. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03150312 · Cited by 141
The treatment of Burkitt lymphoma in adults
Crombie, J. L., & LaCasce, A. S. (2020) · Blood · doi:10.1182/blood.2019004099 · Cited by 139
Oncologic emergencies and urgencies: A comprehensive review
Rothberg, B. E. G., Quest, T. E., Yeung, S. J., Pelosof, L. C., Gerber, D. E., Seltzer, J. A., Bischof, J. J., Thomas, C. R., Akhter, N., Mamtani, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21727 · Cited by 139
Tasian, S. K., & Gardner, R. A. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715588916 · Cited by 117
Onco-Nephrology: AKI in the Cancer Patient
Lam, A. Q., & Humphreys, B. D. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03140312 · Cited by 130
Phosphate toxicity and tumorigenesis
Brown, R. B., & Razzaque, M. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.007 · Cited by 120
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
Alakel, N., Middeke, J. M., Schetelig, J., & Bornhäuser, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s103864 · Cited by 119
“of low-intensity therapy in highly chemosensitive cancers with high tumor burden.(34,35) O nc oT ar ge ts a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .”
Lengliné, É., Raffoux, E., Lemiale, V., Darmon, M., Canet, E., Boissel, N., Schlemmer, B., Dombret, H., & Azoulay, É. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.649752 · Cited by 119
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Zhang, B.-L., Qin, D.-Y., Mo, Z.-M., Li, Y., Wei, W., Wang, Y.-S., Wang, W., & Wei, Y.-Q. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5027-4 · Cited by 105
“Moreover, numerous studies have demonstrated that production of cytokines such as IL-2 and IL-15 improved the anti-tumor effects of CAR-T cells (Hoyos et al., 2010; Kershaw et al., 2006; Nishio and Dotti, 2015; Till et al., 2008; Wang et al., 2013).”
CAR T-cell Therapy: Toxicity and The Relevance of Preclinical Models
Kalaitsidou, M., Kueberuwa, G., Schütt, A., & Gilham, D. E. (2015) · Immunotherapy · doi:10.2217/imt.14.123 · Cited by 112
Crane, J. K., Naeher, T. M., Broome, J. E., & Boedeker, E. C. (2013) · Infection and Immunity · doi:10.1128/iai.01124-12 · Cited by 107
Acute Kidney Injury in Adults With Hemophagocytic Lymphohistiocytosis
Aulagnon, F., Lapidus, N., Canet, E., Galicier, L., Boutboul, D., Péraldi, M., Reuter, D., Bernard, R., Schlemmer, B., Azoulay, É., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.012 · Cited by 105
“Total bilirubin (mmol/L) 26 [13-79] 22 [15-53] 31 [11-91] 0.”
Galliani, M., Diacci, C., Berto, M., Sensi, M., Beni, V., Berggren, M., Borsari, M., Simon, D. T., Biscarini, F., & Bortolotti, C. A. (2020) · Advanced Materials Interfaces · doi:10.1002/admi.202001218 · Cited by 104
Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13
Bolze, P., Riedl, C., Massardier, J., Lotz, J., You, B., Schott, A., Hajri, T., & Golfier, F. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.09.083 · Cited by 104
Williams, S. M., & Killeen, A. A. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0278-rs · Cited by 97
“Urine alkalinization to promote uric acid excretion is no longer recommended because of a lack of clear efficacy and the potential for precipitating xanthine and calcium phosphate in the renal tubules.(2,9,10) Volume status must be very carefully monitored to prevent volume overload, particularly in patients with rena…”
BackgroundInfluentialSpina, M., Nagy, Z., Ribera, J., Federico, M., Aurer, I., Jordan, K., Borsaru, G., Приступа, А. С., Bosi, A., Grosicki, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv317 · Cited by 97
“Tumor lysis syndrome (TLS) is the most common treatment-related emergency in patients with hematologic malignancies (HM) [1, 2].”
BackgroundBaldo, B. A., & Pham, N. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9447-3 · Cited by 95
“This rapidly results in an ionic imbalance involving hyperkalaemia, hyperphosphatemia, hypocalcaemia and hyperuricaemia which may progress to acute renal failure, cardiac arrhythmias, seizures and death [236].”
BackgroundKuo, Y., Hsieh, S., Chen, J., Liu, C., Chen, C., Huang, Y.-F., & Ho, H.-H. (2021) · PeerJ · doi:10.7717/peerj.11209 · Cited by 94
Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects
Poorebrahim, M., Sadeghi, S., Fakhr, E., Abazari, M. F., Poortahmasebi, V., Kheirollahi, A., Askari, H., Rajabzadeh, A., Rastegarpanah, M., Linē, A., et al. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1633512 · Cited by 94
“cytokine release or tumor cell death, which results in CRS and tumor lysis syndrome, respectively [165,166].”
BackgroundIchaï, C., Vinsonneau, C., Souweine, B., Armando, F., Canet, E., Clec’h, C., Constantin, J., Darmon, M., Duranteau, J., Gaillot, T., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0145-5 · Cited by 93
“There are two special conditions requiring the preventive treatment of AKI: (1) high doses of methotrexate infusion [200]; (2) patients with a high-risk of tumour lysis syndrome.”
Roeker, L. E., Fox, C. P., Eyre, T. A., Brander, D. M., Allan, J. N., Schuster, S. J., Nabhan, C., Hill, B. T., Shah, N. N., Lansigan, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0361 · Cited by 92
“) clinical TLS events were defined by the Howard criteria (2).”
Acute Kidney Injury in the Elderly
Rosner, M. H. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.05.001 · Cited by 94
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
Al‐Sawaf, O., Stumpf, J., Zhang, C., Simon, F., Bosch, F., Feyzi, E., Ghia, P., Gregor, M., Kater, A. P., Lindström, V., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2515458 · Cited by 91
Oncologic Emergencies: Recognition and Initial Management.
Higdon, M. L., Atkinson, C. J., & Lawrence, K. V. (2018) · PubMed · Cited by 91
Eyre, T. A., Kirkwood, A. A., Gohil, S. H., Follows, G., Walewska, R. J., Walter, H. S., Cross, M., Forconi, F., Shah, N., Chasty, R., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15802 · Cited by 89
“The rate of TLS in our series is lower than the US RWD set.”
MethodInfluentialZeidan, A. M., Borate, U., Pollyea, D. A., Brunner, A. M., Roncolato, F., Garcia, J. S., Filshie, R., Odenike, O. M., Watson, A. M., Krishnadasan, R., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26771 · Cited by 88
“Laboratory TLS was defined as reported by Howard et al.14 DLT was determined based on the AEs occurring during the DLT observation period defined as the first treatment cycle (Supporting Information).”
MethodMcBride, A., & Westervelt, P. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-75 · Cited by 86
“suggested revisions to the Cairo & Bishop definitions [1].”
InfluentialEnzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects
Baldo, B. A. (2015) · BioDrugs · doi:10.1007/s40259-015-0116-7 · Cited by 85
Postoperative nausea and vomiting in pediatric anesthesia
Höhne, C. (2014) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000073 · Cited by 82
“These electrolyte and metabolic disturbances may progress very fast to clinical toxic effects, including renal insufficiency, cardiac arrhythmias, seizures, and death [26].”
BackgroundSiddiqui, M. R., Railkar, R. S., Sanford, T. H., Crooks, D. R., Eckhaus, M., Haines, D. C., Choyke, P. L., Kobayashi, H., & Agarwal, P. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-38575-x · Cited by 82
Tempark, T., John, S., Rerknimitr, P., Satapornpong, P., & Sukasem, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.832048 · Cited by 80
“Systemic tumor lysis syndrome and spontaneous (idiopathic) cutaneous tumor lysis syndrome are the twomost common types (Cohen et al., 2021).”
BackgroundTumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
Cheson, B. D., Enschede, S. H., Cerri, E., Desai, M. B., Potluri, J., Lamanna, N., & Tam, C. S. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0055 · Cited by 80
“, pre-existing chronic renal insufficiency, oliguria, splenomegaly, dehydration, hypotension, and acidic urine) recommend that patients at high risk of TLS be monitored every 4–6 hours, that those at medium risk be monitored every 8–12 hours after initiation of therapy, and that low-risk patients be monitored daily [1…”
BackgroundMethodInfluentialCombining SERS Analysis of Serum with PSA Levels for Improving the Detection of Prostate Cancer
Ştefancu, A., Moisoiu, V., Couți, R., Andraș, I., Rahota, R., Crișan, D., Pavel, I., Socaciu, C., Leopold, N., & Crişan, N. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0127 · Cited by 80
Current understanding of tumor lysis syndrome
Rahmani, B., Patel, S., Seyam, O., Gandhi, J., Reid, I., Smith, N. L., & Khan, S. A. (2019) · Hematological Oncology · doi:10.1002/hon.2668 · Cited by 79
Yang, Y., Huang, Z., Li, J., Mo, Z., Huang, Y., Ma, C., Wang, W., Pan, X., & Wu, C. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900965 · Cited by 79
Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Matuszkiewicz‐Rowińska, J., & Małyszko, J. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000509934 · Cited by 79
The role of regulated necrosis in endocrine diseases
Tonnus, W., Belavgeni, A., Beuschlein, F., Eisenhofer, G., Faßnacht, M., Kroiß, M., Krone, N. P., Reincke, M., Bornstein, S. R., & Linkermann, A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00499-w · Cited by 79
Baldo, B. A. (2022) · Antibodies · doi:10.3390/antib11010017 · Cited by 77
“Other: A rterial thromboembolic events; IR; RPLS; hypertension; deterioration in patients with cirrhosis; proteinuria including nephrotic syndrome; thyroid dysfunction; embryo-fetal risk Systemic: Hypertension; diarrhea; headache; hytremia; neutropenia; epistaxis; stomatitis; immunogenicity Rituximab (Rituxan®; MabThe…”
BackgroundInfluentialTumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology
Lupusoru, G. E., Ailincăi, I., Frățilă, G., Ungureanu, O., Andronesi, A. G., Lupușoru, M. O. D., Banu, M., Văcăroiu, I. A., Dina, C., & Sinescu, I. C. (2022) · Biomedicines · doi:10.3390/biomedicines10051012 · Cited by 77
“For example, the Berlin–Frankfurt–Muenster group treated a child with ALL by initially administering prednisone for one week before initiating induction chemotherapy [75].”
MethodAllen, K. C., Champlain, A. H., Cotliar, J. A., Belknap, S. M., West, D. P., Mehta, J., & Trifilio, S. M. (2015) · Drug Safety · doi:10.1007/s40264-014-0255-7 · Cited by 76
“While this occurs most frequently in patients with high-grade malignancies receiving aggressive chemotherapy regimens, it may also be seen in patients treated for indolent haematological malignancies, such as chronic lymphocytic leukaemia or multiple myeloma with or without pre-existing renal dysfunction [1].”
InfluentialFlinn, I. W., Gribben, J. G., Dyer, M. J. S., Wierda, W. G., Maris, M. B., Furman, R. R., Hillmen, P., Rogers, K. A., Iyer, S. P., Quillet‐Mary, A., et al. (2019) · Blood · doi:10.1182/blood-2019-01-896290 · Cited by 76
“TLS was classified according to Howard criteria.(27) Response assessments were performed by investigators per iwCLL 2008 criteria,(25) with BM examination and imaging to confirm response, starting from cycle 2 whenever there was clinical indication of response.”
MethodBarbar, T., & Sathick, I. J. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.007 · Cited by 75
Davies, K. J., Barth, M. J., Armenian, S. H., Audino, A. N., Barnette, P., Cuglievan, B., Ding, H., Ford, J. B., Galardy, P. J., Gardner, R. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0036 · Cited by 73
Kumar, A. A., Soumerai, J. D., Abramson, J. S., Barnes, J. A., Caron, P. C., Chhabra, S., Chabowska, M., Doǧan, A., Falchi, L., Grieve, C., et al. (2024) · Blood · doi:10.1182/blood.2024025563 · Cited by 73
How I treat hematologic emergencies in adults with acute leukemia
Zuckerman, T., Ganzel, C., Tallman, M. S., & Rowe, J. M. (2012) · Blood · doi:10.1182/blood-2012-04-424440 · Cited by 72
Durani, U., Shah, N. D., & Go, R. S. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0147 · Cited by 72
“Most studies of TLS outcomes have used relatively small retrospective cohorts [2].”
BackgroundCAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
Zhang, Q., Zhang, Z., Peng, M., Fu, S., Xue, Z., & Zhang, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1251539 · Cited by 71
“rapid lysis of malignant cells, is another potentially fatal complication of CAR-T cell therapy.(32) The delivery of these molecules from the intracellular to the extracellular space could”
BackgroundChoi, M. H., Choe, Y. H., Park, Y., Nah, H., Kim, S., Jeong, S. H., & Kim, H. O. (2017) · Transfusion · doi:10.1111/trf.14329 · Cited by 71
“of leukapheresis procedures 1 11 (34) — 7 (44) — 2 14 (44) 7 (44) 3 7 (22) 2 (13) Time from admission to treatments, hours Leukapheresis 5 [3-24] 8 [4-24] Chemotherapy 73 [25-121] 24 [3-57] 47 [24-94] 24 [4-57] Mortality Early mortality, 2 weeks 0 (0) 2 (5) 0.”
Acute Leukemia: Diagnosis and Treatment
Blackburn, L. M., Bender, S., & Brown, S. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.150950 · Cited by 71
Tvedt, T. H. A., Vo, A. K., Bruserud, Ø., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215190 · Cited by 68
“Second, there is activation of the complement system [63,64].”
Background
Metadata
- Authors
- Howard, S. C., Jones, D. P., & Pui, C.-H.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-12
- Volume
- 364
- Issue
- 19
- Pages
- 1844-1854
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3437249
- OpenAlex
- W2122479144
- Cited by
- 1,044
- References
- 58
- Citations by year
- 2026: 71 · 2025: 67 · 2024: 86 · 2023: 71 · 2022: 69 · 2021: 81 · 2020: 89 · 2019: 154 · 2018: 60 · 2017: 53 · 2016: 49 · 2015: 57 · 2014: 47 · 2013: 49 · 2012: 31
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA21765, P30CA021765)
- National Institute of General Medical Sciences (U01GM92666, U01GM092666)
- Topics
- Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
- Keywords
- tumor lysis syndrome, hematologic malignancies, risk assessment, prophylaxis, treatment, pediatric oncology, emergency management
- MeSH terms
- Child, Humans, Male, Tumor Lysis Syndrome, Risk Assessment, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.